Partnering
We are actively pursuing collaborations for pipeline development.
CELLSELECT™ Proprietary Technologies
BerGenBio’s CellSelect technology platform significantly reduces the risk, time and cost associated with new target and drug discovery. Our deep understanding and focus on cancer biology, tumor micro-environment, escape pathways, drug-resistance, stem cell, and EMT phenotypes provides unique opportunities to our clients and partners.
CELLSELECT™ RNAi
Robust reliable RNAi knockdown for drug target discovery and validation.
CELLSELECT™ Imaging
In vivo and in vitro multimodal imaging and cell recovery.
CELLSELECT™ Regulated
Controlled in vivo knockdown for modeling therapeutic intervention at different disease stages.
CELLSELECT™ Modeling
In vivo and in vitro models of disease and therapeutic activity. 3D human tissue engineering models with human vasculature.
CELLSELECT™ Screening
Dominant effector genetic screens for drug target candidates, mode of action studies and escape pathway identification.